Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Aprea faces another disappointment this week in the clinic. The FDA held up a yellow card, and the Boston-based biotech has placed a partial clinical hold on its myeloid malignancy program.
While the study hit its primary efficacy endpoints, investors are likely concerned about reports of “inconsistent results” regarding reducing Uox excretion in a subtype of patients with the rare disease.
It was a busy week for clinical trial announcements. Take a look.
U.S. authorization is likely not a priority for Novavax since half the population is already vaccinated. But with other parts of the world, there’s still plenty of room for a Novavax vaccine.
Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.
Legal firms are lining up to lead litigation against the company on behalf of shareholders who saw their stock dive.
A United Kingdom watchdog organization has accused Pfizer and Flynn Pharma of violating antitrust rules and overcharging that country’s National Health Services for anti-epilepsy treatments.
Gilead Sciences’ Kite Pharma has entered into a collaboration and licensing agreement with biotech startup Appia Bio, which will focus on the joint research and development of allogeneic cell therapies for cancer.
Top-line results from the Phase II REPAIR trial show a gold nanocrystal suspension, CNM-Au8®, significantly improved brain energetic metabolism in patients with Parkinson’s disease and multiple sclerosis.
CytoDyn files a lawsuit against the activist group led by Rosenbaum and Patterson, alleging that they are “waging an illegal proxy contest to take over control of the Company’s Board of Directors.”
The Phase III trial shows that PD-1 inhibitor Libtayo and platinum-doublet chemotherapy significantly improved OS compared with chemotherapy alone with locally advanced NSCLC.
Tadataka “Tachi” Yamada, a former GlaxoSmithKline and Takeda Pharmaceutical executive, early gene therapy backer, and philanthropist, passed away on Wednesday of natural causes at the age of 76.